CMO Draft Guidance Overly Prescriptive, Out Of Touch – Industry
This article was originally published in The Rose Sheet
Executive Summary
PCPC and other trade groups, as well as firms including Pfizer and Merck, say FDA’s draft guidance on quality agreements between drug contract manufacturers and marketers goes into excessive detail and is inconsistent with actual business arrangements common in the industry.